These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 4106277)

  • 21. [Amenorrhea-galactorrhea following the use of ovosiston].
    Kosowski I; Stojanow G; Iliewa W
    Zentralbl Gynakol; 1973 Jun; 95(25):851-4. PubMed ID: 4126137
    [No Abstract]   [Full Text] [Related]  

  • 22. [Comparison of changes in erythrocyte and resin tests induced by the use of Femigen-forte and Femifen (Polfa) preparations as contraceptives].
    Pisarek-Miedzińska D; Czech W; Firek A
    Ginekol Pol; 1974 Jan; 45(1):57-60. PubMed ID: 4131322
    [No Abstract]   [Full Text] [Related]  

  • 23. [Indications for the treatment with sequence preparations].
    Breckwoldt M; Bettendorf G
    Zentralbl Gynakol; 1969 Aug; 91(35):1147-50. PubMed ID: 4189508
    [No Abstract]   [Full Text] [Related]  

  • 24. Our experience with sequential estrogen-progestin treatments to inhibit ovulation.
    Cittadini E; Quartararo P; Romano F
    Int J Fertil; 1969; 14(2):180-7. PubMed ID: 4181574
    [No Abstract]   [Full Text] [Related]  

  • 25. [Two-stage therapy as a method of hormonal contraception in comparison with compound preparations].
    Rothe K
    Z Gesamte Hyg; 1970 Apr; 16(4):289-90. PubMed ID: 4108397
    [No Abstract]   [Full Text] [Related]  

  • 26. [Provisional results of a clinical study of sequential and combination therapy with oral contraceptives].
    Arnold M; Angst-Horridge A; Burckhardt-Tamm E; Cloeren S; Mall-Haefeli M; Richter RH; Streit-Pfenniger M; Wyss H
    Gynaecologia; 1968; 165(2):218-20. PubMed ID: 4178566
    [No Abstract]   [Full Text] [Related]  

  • 27. [Biphasic therapy using Sequenz-Ovosiston for hormonal contraception].
    Ebeling K; Kühndel K; Rothe K; Canzler E
    Z Arztl Fortbild (Jena); 1971 Dec; 65(24):1275-8. PubMed ID: 4111418
    [No Abstract]   [Full Text] [Related]  

  • 28. The effect of the oral contraceptive Ovosiston on the composition of human milk.
    Ramadan MA; Salah MM; Eid SZ; Sammour MB
    J Reprod Med; 1972 Aug; 9(2):81-3. PubMed ID: 4115112
    [No Abstract]   [Full Text] [Related]  

  • 29. [Intrahepatic cholestasis in hormonal contraception--a case with a difficult and expensive differential diagnosis].
    Böhme HH; Otto HJ
    Zentralbl Gynakol; 1985; 107(5):311-2. PubMed ID: 2581395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Oral contraception and gynecologic therapy].
    Käsemann W
    Med Welt; 1969 Jan; 2():107-10. PubMed ID: 4179615
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Liver function and glucose tolerance during treatment with the oral contraceptive ovosiston].
    Heller H
    Dtsch Gesundheitsw; 1972 Jun; 27(22):1035-8. PubMed ID: 4114489
    [No Abstract]   [Full Text] [Related]  

  • 32. [Steroid metabolism in primates. XVIII. Return to higher levels of 17-ketosteroid excretion in urine after ending a long-term treatment with mestranol/chlormadinone acetate in the baboon].
    Gontscharow NP; Woronzow WI; Schön R; Hobe G; Schubert K
    Endokrinologie; 1976 Jul; 67(3):362-4. PubMed ID: 61857
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of ovulation by estrogens.
    Gual C; Becerra C; Rice-Wray E; Goldzieher JW
    Am J Obstet Gynecol; 1967 Feb; 97(4):443-7. PubMed ID: 4163201
    [No Abstract]   [Full Text] [Related]  

  • 34. [Early tubal abortion during oral contraception].
    Köpernik H; Timmel H
    Zentralbl Gynakol; 1972 Sep; 94(38):1248-52. PubMed ID: 4118175
    [No Abstract]   [Full Text] [Related]  

  • 35. [Evaluation of the efficacy and side effects of the contraceptive containing 0.5 mg of norethindrone and 0.1 mg of mestranol in a family planning clinic].
    de Sampaio Júnior LF; Dib JE; Pereira VM; Neme B
    Matern Infanc (Sao Paulo); 1971; 30(1):65-9. PubMed ID: 5135370
    [No Abstract]   [Full Text] [Related]  

  • 36. [Influence of cyclic Ovosiston therapy on plasma lipid fractions of free cholesterol, total cholesterol and phospholipid].
    Carol W; Hempel E; Klinger G; Bünnig S
    Endokrinologie; 1970; 57(1):108-14. PubMed ID: 4099595
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Experience with Ovosiston for contraception. II].
    Geschke H
    Dtsch Gesundheitsw; 1970 Feb; 25(5):201-6. PubMed ID: 4192921
    [No Abstract]   [Full Text] [Related]  

  • 38. [Serum immunoglobulins and C-reactive protein following oral administration of ovulation inhibitors].
    Gay S; Seidenschnur G; Geiler G
    Dtsch Gesundheitsw; 1972 Jan; 27(1):32-4. PubMed ID: 4111064
    [No Abstract]   [Full Text] [Related]  

  • 39. Cytohormonal findings in patients using various forms of contraception.
    Reyniak JV; Sedlis A; Stone D; Connell E
    Acta Cytol; 1969 Jun; 13(6):315-22. PubMed ID: 4184413
    [No Abstract]   [Full Text] [Related]  

  • 40. [Hopes and failures concerning small-dosage chlormadinone].
    Souleau J
    Bull Fed Soc Gynecol Obstet Lang Fr; 1970; 22(2):185-6. PubMed ID: 4097505
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.